Skip to main content
NTRANatera, Inc.Sell5.5·$390.79

Natera (NTRA) Q2 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+12.0% vs estimateEPS -$0.47 vs -$0.53 estVerdict HoldSell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Adjusted EPS
-$0.47
Estimate
-$0.53
Surprise
+12.0%
Revenue (period 2026-06-30)
$752.8M
Score at report (before → after)
5.85.9/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Natera (NTRA) reported a narrower loss than forecast — adjusted EPS of -$0.47 against the -$0.53 estimate (a 12.0% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.8/10) to Sell at 5.9/10 after the report.

Current read · as of 2026-09-24

Where TrendMatrix's rating stands now

TrendMatrix currently rates NTRA Sell at 5.5/10.

2 of the last 4 quarters beat the estimate; this quarter's +12.0% surprise compares with a +22.6% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Positive news sentiment (+0.53)

What argues against it

  • Analyst target reached - limited upside remaining
  • Near 52-week high (1.0% away)
  • V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$390.79
Price target
$449.41
Stop
$365.75
Upside to target
+15.0%

Risk check: RSI 85 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.

Healthcare context

NTRA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$56.33B
P/E (fwd)
-3751.8
52-week range
$157.43$394.86
Off 52-week high
1.0%
RSI (14)
85
Volume vs avg
1.24×
Score today
5.5/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks NTRA Earnings Q2 2026 earnings